Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Brain Tumor Pathology
Published in: Brain Tumor Pathology 1/2018

01-01-2018 | Original Article

Glioblastoma in neurofibromatosis 1 patients without IDH1, BRAF V600E, and TERT promoter mutations

Authors: Ichiyo Shibahara, Yukihiko Sonoda, Hiroyoshi Suzuki, Akifumi Mayama, Masayuki Kanamori, Ryuta Saito, Yasuhiro Suzuki, Shoji Mashiyama, Hiroshi Uenohara, Mika Watanabe, Toshihiro Kumabe, Teiji Tominaga

Published in: Brain Tumor Pathology | Issue 1/2018

Login to get access

Abstract

Pilocytic astrocytomas and low-grade gliomas are more common compared with glioblastomas in patients with neurofibromatosis 1 (NF1). A recent genome-wide analysis has shown frequent NF1 gene alterations in the mesenchymal subtype of a glioblastoma; however, little is known about clinicopathological features of glioblastomas in NF1 patients (NF1 glioblastomas). We analyzed four NF1 glioblastomas. Radiographical and intraoperative findings showed well-circumscribed tumors from surrounding brain. Pathological analysis presented a paucity of processes with an eosinophilic cytoplasm, bizarre nuclei, xanthomatous-like appearance, multinucleated giant cells, and histiocytoid appearance. During the follow-up period, one patient died at 49 months and others remained alive for 60, 87, and 106 months; thus, patients with NF1 glioblastoma presented a relatively favorable survival. None of the NF1 glioblastomas harbored isocitrate dehydrogenase 1 (IDH1) gene mutation, v-RAF murine sarcoma viral oncogene homolog B1 (BRAF) gene mutation, and telomerase reverse transcriptase (TERT) gene promoter mutation. We identified that NF1 glioblastoma is a unique subset of glioblastoma.
Literature
1.
2.
Neurofibromatosis (1988) Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 45:575–578CrossRef
3.
4.
Gutmann DH, Rasmussen SA, Wolkenstein P et al (2002) Gliomas presenting after age 10 in individuals with neurofibromatosis type 1 (NF1). Neurology 59:759–761CrossRefPubMed
5.
Rodriguez FJ, Perry A, Gutmann DH et al (2008) Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients. J Neuropathol Exp Neurol 67:240–249CrossRefPubMedPubMedCentral
6.
Verhaak RG, Hoadley KA, Purdom E et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110CrossRefPubMedPubMedCentral
7.
Alexandrescu S, Korshunov A, Lai SH et al (2016) Epithelioid glioblastomas and anaplastic epithelioid pleomorphic xanthoastrocytomas-same entity or first cousins? Brain pathology 26:215–223CrossRefPubMed
8.
Kleinschmidt-DeMasters BK, Aisner DL, Birks DK et al (2013) Epithelioid GBMs show a high percentage of BRAF V600E mutation. Am J Surg Pathol 37:685–698CrossRefPubMedPubMedCentral
9.
10.
Sonoda Y, Yokosawa M, Saito R et al (2010) O (6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma. Int J Clin Oncol. https://​doi.​org/​10.​1007/​s10147-010-0065-6
11.
Shibahara I, Sonoda Y, Kanamori M et al (2012) IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas. Int J Clin Oncol 17:551–561CrossRefPubMed
12.
Shibahara I, Sonoda Y, Saito R et al (2013) The expression status of CD133 is associated with the pattern and timing of primary glioblastoma recurrence. Neuro Oncol 15:1151–1159CrossRefPubMedPubMedCentral
13.
Fransen K, Klintenas M, Osterstrom A et al (2004) Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 25:527–533CrossRefPubMed
14.
Sonoda Y, Kumabe T, Nakamura T et al (2009) Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci 100:1996–1998CrossRefPubMed
15.
Eckel-Passow JE, Lachance DH, Molinaro AM et al (2015) Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372:2499–2508CrossRefPubMedPubMedCentral
16.
Weller M, Felsberg J, Hartmann C et al (2009) Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 27:5743–5750CrossRefPubMed
17.
Miyata S, Sugimoto T, Kodama T et al (2005) Adenoid glioblastoma arising in a patient with neurofibromatosis type-1. Pathol Int 55:348–352CrossRefPubMed
18.
Kroh H, Matyja E, Marchel A et al (2004) Heavily lipidized, calcified giant cell glioblastoma in an 8-year-old patient, associated with neurofibromatosis type 1 (NF1): report of a case with long-term survival. Clin Neuropathol 23:286–291PubMed
19.
Jeong TS, Yee GT (2014) Glioblastoma in a patient with neurofibromatosis type 1: a case report and review of the literature. Brain Tumor Res Treat 2:36–38CrossRefPubMedPubMedCentral
20.
Taraszewska A, Bogucki J, Powala A et al (2013) Giant cell glioblastoma with unique bilateral cerebellopontine angle localization considered as extraaxial tumor growth in a patient with neurofibromatosis Type 1. Clin Neuropathol 32:58–65PubMed
21.
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2016) WHO classification of tumours of the central nervous system, 4th edn. IARC Press, Lyon
22.
Laycock-van Spyk S, Thomas N, Cooper DN et al (2011) Neurofibromatosis type 1-associated tumours: their somatic mutational spectrum and pathogenesis. Hum Genom 5:623–690CrossRef
23.
Jones DT, Kocialkowski S, Liu L et al (2008) Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 68:8673–8677CrossRefPubMedPubMedCentral
24.
Adeleye AO, Okolo CA, Akang EE et al (2012) Cerebral pleomorphic xanthoastrocytoma associated with NF1: an updated review with a rare atypical case from Africa. Neurosurg Rev 35:313–319 (discussion 319) CrossRefPubMed
25.
Takei H, Rouah E, Bhattacharjee MB (2015) Cerebellar pleomorphic xanthoastrocytoma in a patient with neurofibromatosis type 1: a case report and literature review. Int J Clin Exp Pathol 8:7570–7574PubMedPubMedCentral
26.
Saikali S, Le Strat A, Heckly A et al (2005) Multicentric pleomorphic xanthoastrocytoma in a patient with neurofibromatosis type 1. Case report and review of the literature. J Neurosurg 102:376–381CrossRefPubMed
27.
Naidich MJ, Walker MT, Gottardi-Littell NR et al (2004) Cerebellar pleomorphic xanthoastrocytoma in a patient with neurofibromatosis type 1. Neuroradiology 46:825–829CrossRefPubMed
28.
Hariharan S, Donahue JE, Garre C et al (2006) Clinicopathologic and genetic analysis of siblings with NF1 and adult-onset gliomas. J Neurol Sci 247:105–108CrossRefPubMed
29.
Rutledge WC, Kong J, Gao J et al (2013) Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class. Clin Cancer Res 19:4951–4960CrossRefPubMed
30.
31.
Singh AD, Iftinca M, Easaw JC (2013) Lipidized glioblastoma: pathological and molecular characteristics. Neuropathology 33:87–92CrossRefPubMed
32.
Gupta K, Kalra I, Salunke P et al (2011) Lipidized glioblastoma: a rare differentiation pattern. Neuropathology 31:93–97CrossRefPubMed
33.
Kanamori M, Suzuki H, Takei H et al (2016) Malignant transformation of diffuse astrocytoma to glioblastoma associated with newly developed BRAF V600E mutation. Brain Tumor Pathol 33:50–56CrossRefPubMed
34.
Arita H, Narita Y, Fukushima S et al (2013) Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol 126:267–276CrossRefPubMed
35.
Matsumura N, Nakajima N, Yamazaki T et al (2017) Concurrent TERT promoter and BRAF V600E mutation in epithelioid glioblastoma and concomitant low-grade astrocytoma. Neuropathology 37:58–63CrossRefPubMed
36.
Huttner AJ, Kieran MW, Yao X et al (2010) Clinicopathologic study of glioblastoma in children with neurofibromatosis type 1. Pediatr Blood Cancer 54:890–896PubMed
37.
Dahiya S, Emnett RJ, Haydon DH et al (2014) BRAF-V600E mutation in pediatric and adult glioblastoma. Neuro Oncol 16:318–319CrossRefPubMed
38.
39.
Philpott C, Tovell H, Frayling IM et al (2017) The NF1 somatic mutational landscape in sporadic human cancers. Hum Genom 11:13CrossRef
40.
Bikowska-Opalach B, Szlufik S, Grajkowska W et al (2014) Pilocytic astrocytoma: a review of genetic and molecular factors, diagnostic and prognostic markers. Histol Histopathol 29:1235–1248PubMed
Metadata
Title
Glioblastoma in neurofibromatosis 1 patients without IDH1, BRAF V600E, and TERT promoter mutations
Authors
Ichiyo Shibahara
Yukihiko Sonoda
Hiroyoshi Suzuki
Akifumi Mayama
Masayuki Kanamori
Ryuta Saito
Yasuhiro Suzuki
Shoji Mashiyama
Hiroshi Uenohara
Mika Watanabe
Toshihiro Kumabe
Teiji Tominaga
Publication date
01-01-2018
Publisher
Springer Singapore
Published in
Brain Tumor Pathology / Issue 1/2018
Print ISSN: 1433-7398
Electronic ISSN: 1861-387X
DOI
https://doi.org/10.1007/s10014-017-0302-z

Other articles of this Issue 1/2018

Brain Tumor Pathology 1/2018 Go to the issue

Original Article

Research of differential expression of sIL1RAP in low-grade gliomas between children and adults

Case Report

Enchondromatosis-associated oligodendroglioma: case report and literature review

Letter to the Editor

RELA fusion-positive anaplastic ependymoma: molecular characterization and advanced MR imaging

Case Report

A case report of adult cerebellar high-grade glioma with H3.1 K27M mutation: a rare example of an H3 K27M mutant cerebellar tumor

Original Article

Tissue microarray analysis for epithelial membrane protein-2 as a novel biomarker for gliomas

Erratum

Erratum to: Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomas